Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Wednesday, October 1, 2014

New Findings on How Glatiramer Acetate Works for Multiple Sclerosis

By Gale Scott | September 29, 2014

 Patients with the relapsing-remitting (RRMS) form of multiple sclerosis (MS) have shown improvement with glatiramer acetate (Copaxone/Teva). But researchers are still uncertain exactly how the drug works.

In research published online Sept. 29 in Jama Neurology a University of Texas Southwestern Medical Center team in Dallas, TX, reported on the ways in which glatiramer acetate affects B cells in these patients.

Nancy Monson, PhD, and colleagues looked at cell samples from 22 patients with MS who were receiving treatment with glatiramer acetate, 22 RRMS patients who were treatment na├»ve, and 15 healthy controls. They found that glatiramer acetate therapy affects several aspects of dysregulated B-cell function in MS. These changes “may contribute to the therapeutic mechanisms of glatiramer acetate,” the team wrote. 

The B cells of patients with RRMS lose the ability to produce the regulatory cytokine interleukin 10. The question for the team was whether glatiramer acetate would normalize cytokine production. 

They found that the therapy affects B-cell function but that “the exact contribution of B-cell-derived cytokines in MS is not clear.” The researchers said they suspect that the drug affects the pathway of B-cell activation.

 “It stands to reason that glatiramer acetate therapy may alter pathways that are important for integrating these activation signals and other key immunologic genes that are modulated by glatiramer acetate therapy,” they wrote.

Continue reading



~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT and up to date, 
Sign-Up for our email
.

WATCH OUR Multiple Sclerosis recorded
 EDUCATIONAL VIDEOS by Topic: 

.


No comments: